calpain inhibitor iv Search Results


calpain inhibitor iv  (MedChemExpress)
92
MedChemExpress calpain inhibitor iv
Calpain Inhibitor Iv, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/calpain inhibitor iv/product/MedChemExpress
Average 92 stars, based on 1 article reviews
calpain inhibitor iv - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
calpain inhibitor iv  (Merck & Co)
90
Merck & Co calpain inhibitor iv
PKC protects hFLNc from <t>calpain</t> 1-dependent proteolysis through phosphorylation of S2623/S2624. A, HEK293 cells transiently expressing hFLNc d22–24 were treated with Gö6976 or PMA as indicated. Subsequently, cell lysates supplemented with 5 mm CaCl2 were incubated with human calpain 1 and the <t>calpain</t> <t>inhibitor</t> IV as indicated. Samples were analyzed by immunoblotting. FLNc*, aminoterminal cleavage product; FLNc#, carboxyterminal cleavage product. B, HEK293 cells expressing hFLNc d22–24 were treated with Gö6976 or PMA as indicated. Calpain 1 was added to cell lysates and activated with CaCl2 or not as indicated. Samples were analyzed by immunoblotting. FLNc*, aminoterminal cleavage product; FLNc#, carboxyterminal cleavage product. C, Quantification of data shown in (B). Percentage of cleaved hFLNc d22–24 was calculated for n = 3 independent experiments. Shown is the mean ± S.E. *p = 0.0442. D, Extracted ion chromatogram of the peptide 2613TVTKSSSSRGSSY2625 derived from calpain-cleaved hFLNc d22–24.For targeted MS analysis using SIM scans, the N-terminal hFLNc d22–24 cleavage product was further digested using GluC. E, Relative quantification of the calpain 1 cleavage-specific hFLNc d22–24 peptide shown in (D). Quantification is based on normalized MS1 signal intensities observed in calpain 1 cleavage experiments using untreated (control), Gö6976- or PMA-treated HEK293 cells expressing hFLNc d22–24. Shown are the mean ± S.E. (n = 4). *p = 0.0345. F, HEK293 cells were transfected with constructs for hFLNc d22–24 WT and respective S2623/S2624 phosphosite mutants (AA, DD mutant). Calpain 1 was added to cell lysates (containing 5 mm CaCl2) as indicated and samples were analyzed by immunoblotting. FLNc*, aminoterminal cleavage product; FLNc#, carboxyterminal cleavage product. G, Quantification of data shown in (F). Percentage of cleaved hFLNc d22–24 was calculated for n = 3 independent experiments. Shown is the mean ± S.E. *p = 0.0245, **p ≤ 0.0078.
Calpain Inhibitor Iv, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/calpain inhibitor iv/product/Merck & Co
Average 90 stars, based on 1 article reviews
calpain inhibitor iv - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


PKC protects hFLNc from calpain 1-dependent proteolysis through phosphorylation of S2623/S2624. A, HEK293 cells transiently expressing hFLNc d22–24 were treated with Gö6976 or PMA as indicated. Subsequently, cell lysates supplemented with 5 mm CaCl2 were incubated with human calpain 1 and the calpain inhibitor IV as indicated. Samples were analyzed by immunoblotting. FLNc*, aminoterminal cleavage product; FLNc#, carboxyterminal cleavage product. B, HEK293 cells expressing hFLNc d22–24 were treated with Gö6976 or PMA as indicated. Calpain 1 was added to cell lysates and activated with CaCl2 or not as indicated. Samples were analyzed by immunoblotting. FLNc*, aminoterminal cleavage product; FLNc#, carboxyterminal cleavage product. C, Quantification of data shown in (B). Percentage of cleaved hFLNc d22–24 was calculated for n = 3 independent experiments. Shown is the mean ± S.E. *p = 0.0442. D, Extracted ion chromatogram of the peptide 2613TVTKSSSSRGSSY2625 derived from calpain-cleaved hFLNc d22–24.For targeted MS analysis using SIM scans, the N-terminal hFLNc d22–24 cleavage product was further digested using GluC. E, Relative quantification of the calpain 1 cleavage-specific hFLNc d22–24 peptide shown in (D). Quantification is based on normalized MS1 signal intensities observed in calpain 1 cleavage experiments using untreated (control), Gö6976- or PMA-treated HEK293 cells expressing hFLNc d22–24. Shown are the mean ± S.E. (n = 4). *p = 0.0345. F, HEK293 cells were transfected with constructs for hFLNc d22–24 WT and respective S2623/S2624 phosphosite mutants (AA, DD mutant). Calpain 1 was added to cell lysates (containing 5 mm CaCl2) as indicated and samples were analyzed by immunoblotting. FLNc*, aminoterminal cleavage product; FLNc#, carboxyterminal cleavage product. G, Quantification of data shown in (F). Percentage of cleaved hFLNc d22–24 was calculated for n = 3 independent experiments. Shown is the mean ± S.E. *p = 0.0245, **p ≤ 0.0078.

Journal: Molecular & Cellular Proteomics : MCP

Article Title: Myofibrillar Z-discs Are a Protein Phosphorylation Hot Spot with Protein Kinase C (PKCα) Modulating Protein Dynamics *

doi: 10.1074/mcp.M116.065425

Figure Lengend Snippet: PKC protects hFLNc from calpain 1-dependent proteolysis through phosphorylation of S2623/S2624. A, HEK293 cells transiently expressing hFLNc d22–24 were treated with Gö6976 or PMA as indicated. Subsequently, cell lysates supplemented with 5 mm CaCl2 were incubated with human calpain 1 and the calpain inhibitor IV as indicated. Samples were analyzed by immunoblotting. FLNc*, aminoterminal cleavage product; FLNc#, carboxyterminal cleavage product. B, HEK293 cells expressing hFLNc d22–24 were treated with Gö6976 or PMA as indicated. Calpain 1 was added to cell lysates and activated with CaCl2 or not as indicated. Samples were analyzed by immunoblotting. FLNc*, aminoterminal cleavage product; FLNc#, carboxyterminal cleavage product. C, Quantification of data shown in (B). Percentage of cleaved hFLNc d22–24 was calculated for n = 3 independent experiments. Shown is the mean ± S.E. *p = 0.0442. D, Extracted ion chromatogram of the peptide 2613TVTKSSSSRGSSY2625 derived from calpain-cleaved hFLNc d22–24.For targeted MS analysis using SIM scans, the N-terminal hFLNc d22–24 cleavage product was further digested using GluC. E, Relative quantification of the calpain 1 cleavage-specific hFLNc d22–24 peptide shown in (D). Quantification is based on normalized MS1 signal intensities observed in calpain 1 cleavage experiments using untreated (control), Gö6976- or PMA-treated HEK293 cells expressing hFLNc d22–24. Shown are the mean ± S.E. (n = 4). *p = 0.0345. F, HEK293 cells were transfected with constructs for hFLNc d22–24 WT and respective S2623/S2624 phosphosite mutants (AA, DD mutant). Calpain 1 was added to cell lysates (containing 5 mm CaCl2) as indicated and samples were analyzed by immunoblotting. FLNc*, aminoterminal cleavage product; FLNc#, carboxyterminal cleavage product. G, Quantification of data shown in (F). Percentage of cleaved hFLNc d22–24 was calculated for n = 3 independent experiments. Shown is the mean ± S.E. *p = 0.0245, **p ≤ 0.0078.

Article Snippet: Calpain inhibitor IV (Merck) was directly added to the lysis buffer at a final concentration of 50 μ m . Subsequent to lysis, cells were incubated in an ultrasonic bath for 20 min at 8 °C and centrifuged for 5 min at 1500 × g . Supernatants were adjusted to the same protein concentration and calpainolysis was started by addition of 5 m m CaCl 2 and 0.85 μg calpain 1 (Merck) per 100 μl reaction volume.

Techniques: Expressing, Incubation, Western Blot, Derivative Assay, Transfection, Construct, Mutagenesis